Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.36−0.04 (-8.94%)
Close on Nov 17, 2026Market cap $87.79MP/E –Yield –
Outlook Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Outlook Therapeutics's profit margin for the twelve months ending Sep 30, 2019 was -423.8%. For fiscal 2025 it was -4416.2%, against -423.8% the year before. The highest annual figure on record is -423.8% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -4416.2% | −3992.4 |
| FY2019 | Sep 30, 2019 | -423.8% | +550.8 |
| FY2018 | Sep 30, 2018 | -974.6% | +44.6 |
| FY2017 | Sep 30, 2017 | -1019.3% | +769.7 |
| FY2016 | Sep 30, 2016 | -1788.9% | −880.9 |
| FY2015 | Sep 30, 2015 | -908.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -1338.8% | −426.2 |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -172.5% | +1408.0 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -760.6% | +331.8 |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -1597.9% | −621.1 |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -912.5% | −663.7 |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -1580.5% | −1360.9 |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -1092.4% | +666.3 |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -976.8% | +1677.4 |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -248.8% | +6051.4 |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -219.6% | +1915.8 |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -1758.7% | +2752.8 |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -2654.2% | −2298.2 |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -6300.2% | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -2135.4% | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -4511.6% | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -356.1% | – |
See a number that looks wrong?